Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTY96S)

Drug Name

Eptacog beta Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
Mantle cell lymphoma	2A85.5	Phase 1/2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Thioredoxin reductase (PRDX5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[3]
Diterpene triepoxide derivative 1	DMYQHER	N. A.	N. A.	Patented	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04419389) APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R). U.S. National Institutes of Health.
2	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.
3	Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9.
4	Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.